JP2022530742A5 - - Google Patents

Info

Publication number
JP2022530742A5
JP2022530742A5 JP2021558521A JP2021558521A JP2022530742A5 JP 2022530742 A5 JP2022530742 A5 JP 2022530742A5 JP 2021558521 A JP2021558521 A JP 2021558521A JP 2021558521 A JP2021558521 A JP 2021558521A JP 2022530742 A5 JP2022530742 A5 JP 2022530742A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chimeric protein
protein complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021558521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530742A (ja
JP7773371B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025423 external-priority patent/WO2020198662A1/en
Publication of JP2022530742A publication Critical patent/JP2022530742A/ja
Publication of JP2022530742A5 publication Critical patent/JP2022530742A5/ja
Priority to JP2025076699A priority Critical patent/JP2025118769A/ja
Application granted granted Critical
Publication of JP7773371B2 publication Critical patent/JP7773371B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021558521A 2019-03-28 2020-03-27 Clec9aベースキメラタンパク質複合体 Active JP7773371B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025076699A JP2025118769A (ja) 2019-03-28 2025-05-02 Clec9aベースキメラタンパク質複合体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962825584P 2019-03-28 2019-03-28
US62/825,584 2019-03-28
US201962906442P 2019-09-26 2019-09-26
US62/906,442 2019-09-26
PCT/US2020/025423 WO2020198662A1 (en) 2019-03-28 2020-03-27 Clec9a-based chimeric protein complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076699A Division JP2025118769A (ja) 2019-03-28 2025-05-02 Clec9aベースキメラタンパク質複合体

Publications (3)

Publication Number Publication Date
JP2022530742A JP2022530742A (ja) 2022-07-01
JP2022530742A5 true JP2022530742A5 (cg-RX-API-DMAC7.html) 2023-03-31
JP7773371B2 JP7773371B2 (ja) 2025-11-19

Family

ID=72609002

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558521A Active JP7773371B2 (ja) 2019-03-28 2020-03-27 Clec9aベースキメラタンパク質複合体
JP2025076699A Pending JP2025118769A (ja) 2019-03-28 2025-05-02 Clec9aベースキメラタンパク質複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025076699A Pending JP2025118769A (ja) 2019-03-28 2025-05-02 Clec9aベースキメラタンパク質複合体

Country Status (8)

Country Link
US (2) US12351614B2 (cg-RX-API-DMAC7.html)
EP (1) EP3947429A4 (cg-RX-API-DMAC7.html)
JP (2) JP7773371B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220012227A (cg-RX-API-DMAC7.html)
CN (2) CN113840833B (cg-RX-API-DMAC7.html)
AU (1) AU2020244880B2 (cg-RX-API-DMAC7.html)
CA (1) CA3133831A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020198662A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
CN113840833B (zh) * 2019-03-28 2025-06-17 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物
US20230374142A1 (en) * 2020-10-05 2023-11-23 Monash University CLEC9A antibodies
CN121443629A (zh) * 2023-06-09 2026-01-30 奥里尼斯生物科学有限公司 基于clec9a的嵌合蛋白制剂

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489116B1 (en) 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
US7947265B2 (en) 2006-08-02 2011-05-24 Mcgill University Fusion proteins and methods for modulation of immune response
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
GB0805159D0 (en) 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
WO2010030671A1 (en) 2008-09-09 2010-03-18 University Of Medicine And Dentistry Of New Jersey Type i interferon antagonists
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
CA2749558C (en) 2008-12-08 2019-01-15 Complix Nv Single-chain antiparallel coiled coil proteins
JP2012521199A (ja) 2009-03-23 2012-09-13 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 免疫応答を調節するための化合物および方法
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
CN102497885A (zh) 2009-09-10 2012-06-13 赛托斯生物技术公司 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途
RU2577299C2 (ru) 2011-07-04 2016-03-10 Олег Ильич Эпштейн Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний
WO2012170072A1 (en) 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
WO2013053008A2 (en) 2011-10-14 2013-04-18 The Walter And Eliza Hall Institute Of Medical Research Molecules which bind clec9a
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
WO2013107791A1 (en) 2012-01-20 2013-07-25 Vib Vzw Targeted mutant alpha-helical bundle cytokines
PL2822575T3 (pl) 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
US20150132302A1 (en) 2012-05-01 2015-05-14 The University Of Sydney Vaccine and uses thereof
WO2014023709A1 (en) 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd8에의 항원 결합 구조체들
CN114732017A (zh) 2013-04-29 2022-07-12 阿格罗塞文公司 包含结合至鞘脂的抗体的农用化学组合物
KR102322510B1 (ko) 2013-07-18 2021-11-08 브이아이비 브이지더블유 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
US9732135B2 (en) 2013-07-19 2017-08-15 Vib Vzw Targeting of human interferon antagonists
CA2918518C (en) 2013-07-19 2022-08-16 Universiteit Gent Targeted modified il-1 family members
MX370565B (es) 2013-07-19 2019-12-17 Vib Vzw Miembros de la familia tnf modificados dirigidos.
SI3030575T1 (sl) 2013-08-08 2018-11-30 Cytune Pharma Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
EP3576765B1 (en) * 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
CN117924493A (zh) 2017-08-09 2024-04-26 奥里尼斯生物科学有限公司 Clec9a结合剂及其用途
EP3664829A4 (en) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
US12655186B2 (en) 2018-01-26 2026-06-16 Orionis Biosciences, Inc. Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
KR20260100427A (ko) * 2018-03-28 2026-06-29 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
EP3833391A4 (en) 2018-08-08 2022-08-10 Orionis Biosciences, Inc. ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF
CN113840833B (zh) * 2019-03-28 2025-06-17 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物

Similar Documents

Publication Publication Date Title
JP2023504914A5 (cg-RX-API-DMAC7.html)
JP2022058385A5 (cg-RX-API-DMAC7.html)
JP2021007390A5 (cg-RX-API-DMAC7.html)
US10214579B2 (en) Fc fusion proteins comprising novel linkers or arrangements
JP2023123649A5 (cg-RX-API-DMAC7.html)
JP5753903B2 (ja) 活性化可能な二重特異性抗体
JP2024153643A5 (cg-RX-API-DMAC7.html)
CN107922486B (zh) 异源二聚体多特异性抗体形式
JP2023518518A5 (cg-RX-API-DMAC7.html)
JP2021020905A5 (cg-RX-API-DMAC7.html)
JP2022512043A5 (cg-RX-API-DMAC7.html)
JP2025060939A5 (cg-RX-API-DMAC7.html)
JP2023553697A5 (cg-RX-API-DMAC7.html)
JP2013506411A5 (cg-RX-API-DMAC7.html)
DK2921503T3 (en) Human antibody to human epidermal growth factor receptor and coding gene and its use
JP2020530770A5 (cg-RX-API-DMAC7.html)
JP2021505156A5 (cg-RX-API-DMAC7.html)
JP2024509904A5 (cg-RX-API-DMAC7.html)
Blanco-Toribio et al. Generation and characterization of monospecific and bispecific hexavalent trimerbodies
JP2024534795A (ja) 二重特異性抗体およびその使用
KR20250028265A (ko) 항체 및 이의 용도
JP2023552462A5 (cg-RX-API-DMAC7.html)
CN113840833B (zh) 基于clec9a的嵌合蛋白复合物
JP2022548364A5 (cg-RX-API-DMAC7.html)
JP2024531346A5 (cg-RX-API-DMAC7.html)